Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e non » _ non (Expand Search), a non (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e non » _ non (Expand Search), a non (Expand Search)
-
121
-
122
-
123
-
124
Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5‑ASA–PABA–MAC and 5‑ASA–PABA–Diamine for the T...
Published 2022“…Specifically, compound <b>20g</b> displayed a 3.67-fold decrease of plasma AUC<sub>(tofacitinib, 0–∞)</sub> and a 9.61-fold increase of colonic AUC<sub>(tofacitinib, 0–12h)</sub>, compared with tofacitinib at a molar equivalent oral dose. …”
-
125
-
126
-
127
Insufficient disulfide bond formation results in a decrease in alkaline phosphatase activity and accumulation of the reduced form of DegP in LCFA-utilizing cells.
Published 2020“…The band corresponding to AP is shown (Mol. wt. ~50 kDa). <i>(C) Compromised DsbA-DsbB machinery is responsible for the decrease in alkaline phosphatase activity in cells utilizing oleate</i>. …”
-
128
-
129
-
130
-
131
-
132
Prognosis and risk factors of chronic kidney disease progression in patients with diabetic kidney disease and non-diabetic kidney disease: a prospective cohort CKD-ROUTE study
Published 2022“…We found that DKD patients have a higher risk to develop 50% eGFR decline endpoint (HR:2.30, 95%CI [1.48–3.58], <i>p</i> < 0.001) and KRT endpoint (HR:1.64, 95%CI [1.13–2.37], <i>p</i> < 0.05) than NDKD patients. …”
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140